Use of imaging in the management of malignant pleural mesothelioma

R E Benamore; M J O'Doherty; J J Entwisle

doi:10.1016/j.crad.2005.05.015

Use of imaging in the management of malignant pleural mesothelioma

R E Benamore, M J O'Doherty, J J Entwisle

PET Imaging Centre Facility

Research output: Contribution to journal › Article › peer-review

50 Citations (Scopus)

Abstract

Malignant pleural mesothelioma (MPM) is an increasingly prevalent tumour. The death rate associated with MPM is predicted to peak in the next 10 years, although radiologists and clinicians will be encountering cases for the next few decades. Contrast-enhanced CT is an established technique for evaluating suspected malignant pleural disease, but MPM can be reliably diagnosed only by histological sampling. However, even with adequate sampling and the use of immunocytochemistry, histological diagnosis is known to be difficult; definitive diagnosis may involve a combination of clinical presentation, radiological and histological appearances. Percutaneous biopsy is a promising technique for sampling the pleura. In view of its pattern of growth, MPM is a challenging disease to image by any method, and it behaves quite differently from lung cancer. This review aims to highlight the practical aspects of assessing malignant pleural mesothelioma.

Original language	English
Pages (from-to)	1237-1247
Number of pages	11
Journal	Clinical Radiology
Volume	60
Issue number	12
DOIs	https://doi.org/10.1016/j.crad.2005.05.015
Publication status	Published - Dec 2005

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.crad.2005.05.015

Cite this

@article{57b248a2dcd94c898c78283aab197fbc,

title = "Use of imaging in the management of malignant pleural mesothelioma",

abstract = "Malignant pleural mesothelioma (MPM) is an increasingly prevalent tumour. The death rate associated with MPM is predicted to peak in the next 10 years, although radiologists and clinicians will be encountering cases for the next few decades. Contrast-enhanced CT is an established technique for evaluating suspected malignant pleural disease, but MPM can be reliably diagnosed only by histological sampling. However, even with adequate sampling and the use of immunocytochemistry, histological diagnosis is known to be difficult; definitive diagnosis may involve a combination of clinical presentation, radiological and histological appearances. Percutaneous biopsy is a promising technique for sampling the pleura. In view of its pattern of growth, MPM is a challenging disease to image by any method, and it behaves quite differently from lung cancer. This review aims to highlight the practical aspects of assessing malignant pleural mesothelioma.",

author = "Benamore, {R E} and O'Doherty, {M J} and Entwisle, {J J}",

year = "2005",

month = dec,

doi = "10.1016/j.crad.2005.05.015",

language = "English",

volume = "60",

pages = "1237--1247",

journal = "Clinical Radiology",

issn = "0009-9260",

publisher = "W.B. Saunders Ltd",

number = "12",

}

TY - JOUR

T1 - Use of imaging in the management of malignant pleural mesothelioma

AU - Benamore, R E

AU - O'Doherty, M J

AU - Entwisle, J J

PY - 2005/12

Y1 - 2005/12

N2 - Malignant pleural mesothelioma (MPM) is an increasingly prevalent tumour. The death rate associated with MPM is predicted to peak in the next 10 years, although radiologists and clinicians will be encountering cases for the next few decades. Contrast-enhanced CT is an established technique for evaluating suspected malignant pleural disease, but MPM can be reliably diagnosed only by histological sampling. However, even with adequate sampling and the use of immunocytochemistry, histological diagnosis is known to be difficult; definitive diagnosis may involve a combination of clinical presentation, radiological and histological appearances. Percutaneous biopsy is a promising technique for sampling the pleura. In view of its pattern of growth, MPM is a challenging disease to image by any method, and it behaves quite differently from lung cancer. This review aims to highlight the practical aspects of assessing malignant pleural mesothelioma.

AB - Malignant pleural mesothelioma (MPM) is an increasingly prevalent tumour. The death rate associated with MPM is predicted to peak in the next 10 years, although radiologists and clinicians will be encountering cases for the next few decades. Contrast-enhanced CT is an established technique for evaluating suspected malignant pleural disease, but MPM can be reliably diagnosed only by histological sampling. However, even with adequate sampling and the use of immunocytochemistry, histological diagnosis is known to be difficult; definitive diagnosis may involve a combination of clinical presentation, radiological and histological appearances. Percutaneous biopsy is a promising technique for sampling the pleura. In view of its pattern of growth, MPM is a challenging disease to image by any method, and it behaves quite differently from lung cancer. This review aims to highlight the practical aspects of assessing malignant pleural mesothelioma.

U2 - 10.1016/j.crad.2005.05.015

DO - 10.1016/j.crad.2005.05.015

M3 - Article

C2 - 16291305

SN - 0009-9260

VL - 60

SP - 1237

EP - 1247

JO - Clinical Radiology

JF - Clinical Radiology

IS - 12

ER -

Use of imaging in the management of malignant pleural mesothelioma

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this